SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination

By

Authors: Antonietta M. Gatti and Stefano Montanari Abstract Vaccines are being under investigation for the possible side effects they can cause. In order to supply new information, an electron-microscopy investigation method was applied to the study of vaccines, aimed at verifying the presence of solid contaminants by means of an Environmental Scanning Electron Microscope equipped with […]

[Continue reading...]

Vitamin D Levels, Antibody Titers Produced in Response

By

Do Vitamin D Levels Affect Antibody Titers Produced in Response to HPV Vaccine? Antibody Titers Produced in Response Authors: Zimmerman RK1, Lin CJ, Raviotta JM, Nowalk MP. Abstract In addition to its well-known effects on bone metabolism, vitamin D is an immunomodulating hormone. Serum vitamin D levels in males 18-25 years were measured at baseline, and HPV […]

[Continue reading...]

Merck Sharpe and Dohme and Sanofi Pasteur begin new vaccine trial

By Leave a Comment

Posted on 26/04/2011 in Pharmaceutical Company Product News Merck Sharpe and Dohme and its partner Sanofi Pasteur have commenced a clinical study of a new vaccine designed to treat a range of diseases among children. The companies have begun a phase III study of the hexavalent combination vaccine that will test the safety and immunogenicity […]

[Continue reading...]

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24—45 years: a randomised, double-blind trial

By

The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009 doi:10.1016/S0140-6736(09)60691-7:  Munoz, et al   Background: Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and […]

[Continue reading...]

Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients

By

This study is currently recruiting participants. Verified by University of Alberta, February 2010 Official Title Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Purpose Human papillomavirus (HPV) affects a significant number of transplant patients. In women, human papillomavirus (HPV) causes genital warts, pre-cancerous areas of the cervix, and cervical cancer. […]

[Continue reading...]

Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men.

By Leave a Comment

Pubmed
J Infect Dis. 2010 Sep 2

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

Abstract
Background. Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types. Methods. AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination. Results. There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed. Conclusions. The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526 .

PMID: 20812850 [PubMed – as supplied by publisher]

[Continue reading...]

News

Videos

Contact